BengtssonNE, SetoJT, HallJK, et al.Progress and prospects of gene therapy clinical trials for the muscular dystrophies. Hum Mol Genet, 2016; 25:R9–17.
2.
DuanD. Dystrophin gene replacement and gene repair therapy for Duchenne muscular dystrophy in 2016. Hum Gene Ther Clin Dev, 2016; 27:9–18.
3.
MuntoniF, FletcherS, WiltonS. Response to “Railroading at the FDA”. Nat Biotechnol, 2017; 35:207–209.
4.
MendellJR. Eteplirsen improves function and partially restores. Ann Neurol, 2017; 81:164–165.
5.
HaasM, VlcekV, BalabanovP, et al.European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene. Neuromuscul Disord, 2015; 25:5–13.
6.
LaiY, YueY, LiuM, et al.Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol, 2005; 23:1435–1439.
7.
ZhangY, YueY, LiL, et al.Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy. Hum Mol Genet, 2013; 22:3720–3729.
8.
YueY, PanX, HakimCH, et al.Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus. Hum Mol Genet, 2015; 24:5880–5890.
9.
BostickB, ShinJ-H, YueY, et al.AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice. Mol Ther, 2011; 19:1826–1832.
10.
GregorevicP, AllenJM, MinamiE, et al.rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med, 2006; 12:787–789.
ZhangF. CRISPR-Cas9: prospects and challenges. Hum Gene Ther, 2015; 26:409–410.
13.
MakarovaKS, WolfYI, AlkhnbashiOS, et al.An updated evolutionary classification of CRISPR-Cas systems. Nat Rev Microbiol, 2015; 13:722–736.
14.
LongC, McAnallyJR, SheltonJM, et al.Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science, 2014; 345:1184–1188.
15.
LongC, AmoasiiL, MireaultAA, et al.Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science, 2016; 351:400–403.
16.
NelsonCE, HakimCH, OusteroutDG, et al.In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science, 2016; 351:403–407.
17.
TabebordbarM, ZhuK, ChengJK, et al.In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science, 2016; 351:407–411.
18.
OusteroutDG, KabadiAM, ThakorePI, et al.Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun, 2015; 6:6244.
19.
WojtalD, KemaladewiDU, MalamZ, et al.Spell checking nature: versatility of CRISPR/Cas9 for developing treatments for inherited disorders. Am J Hum Genet, 2016; 98:1-–2.
20.
XuL, ParkKH, ZhaoL, et al.CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice. Mol Ther, 2016; 24:564–569.
21.
BengtssonNE, HallJK, OdomGL, et al.Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat Commun, 2017; 8:14454.
22.
LiHL, FujimotoN, SasakawaN, et al.Engineered nuclease mediated genetic correction in iPSCs derived from Duchenne muscular dystrophy patient. Mol Ther, 2014; 22:S124–S124.
23.
YoungCS, HicksMR, ErmolovaNV, et al.A Single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells. Cell Stem Cell, 2016; 18:533–540.
24.
MaggioI, StefanucciL, JanssenJM, et al.Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations. Nucleic Acids Res, 2016; 44:1449–1470.
25.
BursteinD, HarringtonLB, StruttSC, et al.New CRISPR-Cas systems from uncultivated microbes. Nature, 2017; 542:237–241.
26.
AbudayyehOO, GootenbergJS, KonermannS, et al.C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science, 2016; 353.
27.
ShmakovS, AbudayyehOO, MakarovaKS, et al.Discovery and functional characterization of diverse class 2 CRISPR-Cas systems. Mol Cell, 2015; 60:385–397.
28.
ZetscheB, GootenbergJS, AbudayyehOO, et al.Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell, 2015; 163:759–771.
29.
ZhangY, LongC, LiH, et al.CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice. Sci Adv, 2017; 3:e1602814.
30.
WiltonSD, LloydF, CarvilleK, et al.Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord, 1999; 9:330–338.
31.
van DeutekomJC, JansonAA, GinjaarIB, et al.Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med, 2007; 357:2677–2686.
32.
YuasaK, MiyagoeY, YamamotoK, et al.Effective restoration of dystrophin-associated proteins in vivo by adenovirus-mediated transfer of truncated dystrophin cDNAs. FEBS Lett, 1998; 425:329–336.
33.
MendellJR, Rodino-KlapacLR, RosalesXQ, et al.Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol, 2010; 68:629–638.
34.
ZetscheB, HeidenreichM, MohanrajuPet al.Multiplex gene editing by CRISPR-Cpf1 using a single crRNA array. Nat Biotechnol, 2017; 35:31–34.
